ClinicalTrials.gg
CompletedNCT01205568CBUpdated Aug 27, 2026Results posted

Cutting Balloon Study

An interventional study of Transcatheter Cutting Balloon therapy and High Pressure Balloon Angioplasty in Pulmonary Artery Stenosis, sponsored by Boston Children's Hospital. Completed at 6 sites in United States. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 7 years 1 month after the study started (first participant enrolled Aug 2003, registered Sep 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
0 Years to 18 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety and efficacy of transcatheter Cutting Balloon therapy for branch pulmonary artery stenosis resistant to low pressure dilation.

Read the detailed description

The proposed study will be a prospective, multi-center, randomized, blinded trial comparing 2 treatments for pulmonary artery stenosis. Specifically, vessels that fail to respond to balloon inflation at 8 ATM will be individually randomized to 1 of 2 treatment pathways. In the first treatment pathway, the vessel is dilated using a CB, followed by additional low pressure balloon dilation (\< 8ATM). In the second pathway,the vessel is dilated with high pressure balloon angioplasty, with balloon inflation pressures exceeding 15 ATM. Cross-over therapy will be permitted for failed high pressure treatment starting with enrollment of patient #15. The primary outcome assessment for efficacy will be a comparison of percent change in minimum lumen diameter before and after randomized therapy, as determined by a core laboratory blinded to pathway assignment. The primary outcome assessment for safety will be a comparison of the proportion of vessel dilations resulting in any serious adverse events, as determined by the Data and Safety Monitoring Board. Patient-level safety endpoints will also be tabulated. Patients can have multiple vessels enrolled; analytical techniques will adjust for potential intra-patient correlation.

02

Conditions studied

  • Pulmonary Artery Stenosis
03

In context

Lead sponsor

Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient Inclusion Criteria (Determined Prior to Cardiac Catheterization)

a. At least 1 branch pulmonary artery stenosis referred for planned catheterization for PA dilation b. At least one of the following: i.greater than one half systemic right ventricular pressure ii. regional decrease in pulmonary blood flow by lung scan iii. elevated pulmonary artery pressures (> 20 mmHg MPAP) iv. cyanosis at least in part due to PA stenosis c. of patient and/or parent/guardian; assent of mature minors d. Agreement to participate in protocol, including follow-up testing

Vessel Inclusion Criteria (Determined During Cardiac Catheterization)

  1. Native pulmonary artery or branch which fails balloon dilation up to 8 ATM; as defined by failure to eliminate a waist
  2. Native pulmonary artery or branch with a balloon waist diameter less than 7.5 mm (i.e.,0.5 mm less than the largest available CB) with dilation at 8 ATM
  3. All eligible vessels that are dilated during the catheterization must be enrolled as study vessels; "off-study" use of Cutting Balloons or high pressure dilations in eligible vessels is not allowed.

Exclusion criteria

Exclusion Criteria:

3. Patient Exclusion Criteria (Determined Prior to Cardiac Catheterization)

  1. Prior pulmonary artery angioplasty or surgery on the vessel within the previous 6 weeks
  2. Pregnancy

Vessel Exclusion Criteria (Determined During Cardiac Catheterization)

  1. Vessel with an aneurysm from a prior dilation or surgery, defined as a local enlargement of the vessel greater than 100% of the lumen diameter both proximally and distally to the aneurysm. The maximum aneurysm diameter and vessel lumen diameter proximal and distal to the aneurysm will be recorded. The location of the aneurysm relative to the angioplasty site will be determined and reported as proximal, distal, or in the region of waist formation.
  2. Prior stent placement associated with the obstruction

i. balloon inflation for the purpose of expanding the diameter of the stent along its length with no residual waist proximal or distal to the stent edges ii. balloon inflation resulting in waist formation within the edges of a stent iii. dilation of a vessel through the cells of a stent c. Unifocalized nor non-unifocalized systemic to pulmonary artery collaterals. d. A vessel requiring therapy at a site not amenable to delivery or safe positioning of a Cutting Balloon device due to unfavorable anatomy as determined by the physician and based on as assessment of vessel angles, size, length, and proximity to other vessels.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Patients with Resistant Pulmonary Artery Stenosis

    Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation

    Device: Transcatheter Cutting Balloon therapy · Procedure: High Pressure Balloon Angioplasty

Interventions

  • DeviceTranscatheter Cutting Balloon therapy
  • ProcedureHigh Pressure Balloon Angioplasty
06

What researchers measure

Primary outcomes

  1. Acute Change in Minimum Lumen Diameter Immediately Post-intervention

    The primary efficacy outcome is the percent change in minimum lumen diameter from pre-intervention to immediately post-intervention as measured by angiography.

    Time frame: Pre-intervention to immediate post-intervention (approximately 10 minutes)

Secondary outcomes

  1. Percent Change in Minimum Lumen Diameter at 3 Months Post-intervention

    Late percent change in minimum lumen diameter from pre-intervention to follow-up angiography.

    Time frame: 3 months post-intervention

07

Results

Posted May 25, 2018

Participant flow

Participant flow — Overall Study
MilestoneCutting Balloon (CB)High Pressure Balloon (HPB)
Started6547
Completed6547
Not completed00

Outcome measures

PrimaryAcute Change in Minimum Lumen Diameter Immediately Post-intervention

The primary efficacy outcome is the percent change in minimum lumen diameter from pre-intervention to immediately post-intervention as measured by angiography.

Time frame:
Pre-intervention to immediate post-intervention (approximately 10 minutes)
Reported as:
Mean · percentage change
Acute Change in Minimum Lumen Diameter Immediately Post-intervention
percentage changePatients With Resistant Pulmonary Artery Stenosis
Cutting Balloon85.1 ± 77.1
High Pressure Balloon Dilation52.4 ± 66
SecondaryPercent Change in Minimum Lumen Diameter at 3 Months Post-intervention

Late percent change in minimum lumen diameter from pre-intervention to follow-up angiography.

Time frame:
3 months post-intervention
Reported as:
Mean · percent change
Percent Change in Minimum Lumen Diameter at 3 Months Post-intervention
percent changePatients With Resistant Pulmonary Artery Stenosis
Cutting Balloon75.6 ± 97.8
High Pressure Balloon Dilation42.2 ± 66.9

Adverse events

Collected over Patients were monitored for adverse events from the time of enrollment to follow-up assessment 2-4 months after the intervention.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With Resistant Pulmonary Artery Stenosis—0/73 (0%)16/73 (21.9%)
Most frequent other events
Most frequent other events
EventPatients With Resistant Pulmonary Artery Stenosis
Pulmonary EdemaCardiac disorders10/73
Balloon RuptureCardiac disorders3/73
Device malfunctionCardiac disorders2/73
Balloon caught on stentCardiac disorders1/73
Fracture of catheter shaftCardiac disorders1/73
Intravascular tearCardiac disorders1/73
Hemoptysis, hypotensionCardiac disorders1/73
Heart BlockCardiac disorders1/73

Baseline characteristics

Baseline data prior to vessel randomization

Age, Categorical
Age, Categorical(Participants)Patients With Resistant Pulmonary Artery Stenosis
<=18 years72
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Patients With Resistant Pulmonary Artery Stenosis
Female33
Male40
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Patients With Resistant Pulmonary Artery Stenosis
Region of Enrollment
Region of Enrollment(participants)Patients With Resistant Pulmonary Artery Stenosis
United States73
Greater than 1/2 systemic RV pressure
Greater than 1/2 systemic RV pressure(Participants)Patients With Resistant Pulmonary Artery Stenosis
Count of participants60
Regional decrease in pulmonary flow
Regional decrease in pulmonary flow(Participants)Patients With Resistant Pulmonary Artery Stenosis
Count of participants58
Elevated PA pressure (mean >20)
Elevated PA pressure (mean >20)(Participants)Patients With Resistant Pulmonary Artery Stenosis
Count of participants47
Cyanosis in part due to PA stenosis
Cyanosis in part due to PA stenosis(Participants)Patients With Resistant Pulmonary Artery Stenosis
Count of participants19
08

Study locations

6 sites
  • University of California at San Francisco
    San Francisco, California 94143-0130, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Children's Hospital, Philadelphia
    Philadelphia, Pennsylvania 19104-4399, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2003 to primary completion in Mar 2009, 67 months.

Results were first posted in May 2018, 9 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2010
First posted
Sep 20, 2010
StartActual
Aug 1, 2003
Primary completionActual
Mar 17, 2009
CompletionActual
Sep 9, 2009
Results first posted
May 25, 2018
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01205568
Responsible party
Kathy Jenkins (Professor of Pediatrics, Boston Children's Hospital) — Principal investigator
First posted
Sep 20, 2010
Start date
Aug 1, 2003
Primary completion
Mar 17, 2009
Completion
Sep 9, 2009
Results posted
May 25, 2018
Last update
Aug 27, 2026

Study contacts

Kathy Jenkins, MD, MPH
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion